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Despite the lack of formal immunotoxicity testing guidelines, the assessment of immune function has been 
a routine component of toxicity testing for over twenty years. The European Agency for the Evaluation of 
Medicinal Products (EMEA) and The US Food and Drug Administration (FDA) have recently adopted new 
guidelines for immunotoxicity testing of new medicinal products. These two guidelines are compared in 
this article.
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The use of immunologic endpoints in toxicologic 
assessment of drugs and chemicals has led to the 
development of immunotoxicology as a scientific 
discipline (1). Immunotoxicology is defined as the 
study of the adverse effects of occupational or 
therapeutic exposure to chemical or biological material 
on the immune system. Immunotoxicology was born 
in the late 1960s and early 1970s, and in the mid to 
late 1980s it was already in full bloom (2, 3, 4). The 
First International Conference on Immunotoxicology 
was held in 1983. In the 1990s, regulatory agencies 
started to include immunotoxicology data in their risk 
assessment procedures (2, 5).
EMEA AND FDA IMMUNOTOXICITY GUIDELINES
The European Agency for the Evaluation of 
Medicinal Products (EMEA) and The US Food and Drug 
Administration (FDA) recently published guidelines 
addressing the investigation of immunotoxicity of new 
medicinal products. 
In July 2000, the CPMP (Committee for Proprietary 
Medicinal Products) within EMEA adopted a new 
version of Note for Guidance on Repeated Dose 
Toxicity (6). This Note for Guidance was first adopted 
in October 1983 and has been updated with Guidance 
on Immunotoxicity.
In October 2002, the Center for Drug Evaluation 
and Research (CDER), Food and Drug Administration 
published the Guidance for Immunotoxicology 
Evaluation of Investigational New Drugs (7). 
Both guidelines define that all new medicinal 
products should be screened for immunotoxic 
potential within the preclinical evaluation of drug 
toxicity (in at least one repeated dose toxicity study, 
generally incorporated within standard rat 28 day 
toxicity study). They also emphasise a weight-of-
evidence approach to immunotoxicity evaluation as 
opposed to implementing a standard set of tests to 
be conducted with every investigational drug. Both 
guidelines recommend tiered testing approach as 
the optimal strategy for the assessment of medicinal 
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products. Figure 1 shows the algorithm of Tiered 
testing and neither applies to either biotechnology-
derived medicinal products or vaccines. 
There are some differences in recommended 
parameters that should be evaluated in the initial 
screening phase (Tier 1, Figure 1) between the 
EMEA and FDA guidelines. The FDA guidelines 
recommend determining serum biochemical markers 
such as globulin levels in the initial screening phase. 
However, decreased basal serum globulin level is 
a relatively insensitive indicator, because under 
normal circumstances the immune system should 
be challenged with antigen and a particular antibody 
response evaluated to detect immunosupression. 
On the other hand, EMEA recommends additional 
functional parameters such as the distribution of 
lymphocyte subsets and NK-cell activity as a part of 
the screening phase. If these two are unavailable, 
the initial screening phase should be completed with 
the primary antibody response to a T-cell-dependent 
antigen (e.g. sheep red blood cells). Phenotyping and 
the NK-cell activity assay can be incorporated in the 
existing 28-day animal study but T-cell-dependent 
antibody response assay requires an additional subset 
of animals.
The T-cell-dependent antibody response assay is 
described in the FDA guideline as the best general-
purpose functional assay, and it is recommended 
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Lymphoid organ weights (thymus, spleen, draining and 
distant lymph nodes)
Microscopy of lymphoid tissues (thymus, spleen, 
draining and distant lymph nodes, Peyers patches)
Bone marrow cellularity
Distribution of lymphocyte subsets
NK-cell activity
If later two are unavailable: primary antibody response 
to a T-cell dependent antigen (e.g. sheep red blood 
cells) should be done
Haematology 
Lymphoid organ weights (thymus, spleen, 
draining and distant lymph nodes)
Microscopy of lymphoid tissues (thymus, 




Table 2  List of specialized assays defined in FDA guideline on immunotoxicity
MEDICINAL PRODUCT ADDITIONAL ASSAYS REQUIRED
TOPICAL APPLICATION Sensitising potential (Guinea pig maximization test (GPMT), Buehler assay (BA), The murine Local lymph node assay (LLNA))
INHALANT
Respiratory sensitising potential (IgE response in mice following 
dermal exposure, serum cytokine patterns induced by topical 
exposure, LLNA)
INDICATED FOR HIV INFECTION Additional immune function studies as a part of the standard nonclinical assessment
FOR USE IN PREGNANT WOMEN Effect of drug on immune system in F1 offspring in reproductive toxicology (Developmental immunotoxicity)
ACCUMULATED IN IMMUNE SYSTEM TISSUES Additional immune function studies as a part of the standard nonclinical assessment
Figure 1  Algorithm of tiered testing approach in immunotoxicity testing 
of medicinal products
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as additional study (Tier 2, Figure 1). It should be 
performed if the results from screening phase demand 
further studies.
Table 1 compares the lists of parameters that 
should be observed in the screening phase according 
to the EMEA and FDA guidelines.
Additionally, the FDA guidelines define that, 
in certain cases, medicinal products may require 
specialised assays to assess their immunotoxic 
potential. These assays are listed in Table 2. This 
is something that is not specified in the EMEA 
guideline.
CONCLUSION
There is a great debate going on between 
toxicologists as to what is necessary to be compliant 
with both EMEA and FDA regulations as well as 
what studies are required (5). It seems that there is 
a need for the European Community, the USA, and 
Japan to harmonize approaches in immunotoxicity 
testing, either within the context of the International 
Conference of Harmonization (ICH) or outside this 
process.
However, guidelines are not mandatory, they are a 
starting point rather than an end point. Immunotoxicity 
testing requires scientific flexibility. No guideline can 
provide sufficient information to cover all possible 
cases; all persons involved should be willing to discuss 
and consider variations in testing strategy according 
to the state of art and ethical standards in animal 
experimentation. Emphasis on the objectives of the 
study rather than on adherence to a rigid protocol 
allows the design of a test programme which will make 
it appropriate for the tested compound.
The objectives of immunotoxicity testing should 
be the identification of potential target organs, 
characterisation of toxic effects, identification of 
dose response relationship, potential reversibility, and 
identification of parameters for clinical monitoring.
At the end of immunotoxicity testing, toxicologists 
should be able to answer several “simple” questions: 
What is happening in animals? Why is it happening? 
When (in what dose range)? How does it apply to 
humans? 
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Sažetak
USPOREDBA SMJERNICA O ISPITIVANJU IMUNOTOKSIÈNOSTI LIJEKOVA 
Iako donedavno nisu postojale službene smjernice o ispitivanju imunotoksiènosti lijekova, ispitivanja utjecaja 
lijekova na imunosni sustav dio su rutinskih ispitivanja toksiènosti lijekova veæ više od 20 godina. U proteklih 
nekoliko godina i Europska agencija za evaluaciju lijekova i Amerièka agencija za hranu i lijekove objavile 
su smjernice o ispitivanju imunotoksiènosti lijekova koje su u ovom radu usporeðene. 
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